Loading...
Market
In how many countries will ORLYNVAH receive regulatory approval by the end of 2025?
2
Resolution / Starting Odds
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
Official announcements from Iterum Therapeutics or international regulatory bodies
Story
FDA Approves Iterum's Oral Antibiotic ORLYNVAH for Uncomplicated UTIs in Women on October 25, 2024
Oct 25, 2024, 03:58 PM
The U.S. Food and Drug Administration (FDA) has approved Iterum Therapeutics' oral antibiotic, ORLYNVAH, for the treatment of uncomplicated urinary tract infections (UTIs) in adult women. This announcement was made on Friday, October 25, 2024. The approval is significant as it addresses a common health issue among women, providing a new treatment option. The FDA's decision follows a period of heightened trading activity for Iterum Therapeutics, indicated by a notable increase in volume prior to the announcement. The company's market capitalization remains low, suggesting potential for growth following this approval.
View original story
Similar markets
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31 or more countries • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%